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We performed a meta-analysis of all published studies relating intratumoural microvessel density (MVD) (45 studies) or vascular
endothelial growth factor (VEGF) expression (27 studies), both reflecting angiogenesis, to relapse free (RFS) and overall survival (OS)
in colorectal cancer (CRC). For each study, MVD impact was measured by risk ratio between the two survival distributions with
median MVD as cutoff. Eleven studies did not mention survival data or fit inclusion criteria, six were multiple publications of same
series, leaving 32 independent studies for MVD (3496 patients) and 18 for VEGF (2050 patients). Microvessel density was assessed by
immunohistochemistry, using antibodies against factor VIII (16 studies), CD31 (10 studies) or CD34 (seven studies). Vascular
endothelial growth factor expression was mostly assessed by immunohistochemistry. Statistics were performed for MVD in 22
studies (the others lacking survival statistics) including nine studies (n¼957) for RFS and 18 for OS (n¼2383) and for VEGF in 17
studies, including nine studies for RFS (n¼1064) and 10 for OS (n¼1301). High MVD significantly predicted poor RFS (RR¼2.32
95% CI: 1.39–3.90; Po0.001) and OS (RR¼1.44; 95% CI: 1.08–1.92; P¼0.01). Using CD31 or CD34, MVD was inversely related
to survival, whereas it was not using factor VIII. Vascular endothelial growth factor expression significantly predicted poor RFS
(RR¼2.84; 95% CI: 1.95–4.16) and OS (RR¼1.65; 95% CI: 1.27–2.14). To strengthen our findings, future prospective studies
should explore the relation between MVD or VEGF expression and survival or response to therapy (e.g. antiangiogenic therapy).
Assessment of these angiogenic markers should be better standardised in future studies.
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Colorectal cancer (CRC) is the third most common cancer and the
fourth most frequent cause of cancer deaths worldwide (Weitz
et al, 2005). The main prognostic factors in CRC are lymph node
involvement, size of the tumour and local diffusion of disease
(Hellman and Rosenberg, 2001; Hermanek and Sobin, 1995).
However, these prognostic factors do not fully predict individual
clinical outcome especially among stage II and III patients.
Therefore, to improve clinical care, biological prognostic markers
must be identified, especially for localised tumours.
Angiogenesis consists in the formation of new blood vessels
from the endothelium of the existing vasculature. When a new
tumour reaches the size of 1–2mm, its ulterior growth requires
the induction of new blood vessels, which may lead to the
development of metastases. Angiogenesis is dependent on the
balance between many stimulatory and inhibitory factors.
Proangiogenic factors, such as vascular endothelial growth factor
(VEGF), bind to sites on endothelial cells that lead to their
proliferation.
Concerning the relationship between angiogenesis and clinical
outcome, CRC has been one of the most studied tumours after
breast cancer (Uzzan et al, 2004). Microvessel density (MVD), as a
surrogate marker of tumoral angiogenesis, has been proposed to
identify patients at high risk of recurrence. Microvessel density
assessment is the most commonly used technique to quantify
intratumoral angiogenesis in cancer. It was first developed by
Weidner et al (1991) in 1991 and used panendothelial immuno-
histochemical staining of blood microvessels, mainly with Factor
VIII related antigen (F. VIII Ag or von Willebrand’s factor), CD31
or CD34, rarely CD105. Some authors used Chalkley count or
computerised image analysis systems, both aimed to minimise the
subjectivity in the quantification of MVD (Chalkley, 1943).
Several methods were employed for the assessment of VEGF
expression in the tumours: most often immunohistochemistry, but
also RT–PCR or Northern Blot. Circulating VEGF may be related
to the tumour, but is also certainly produced by platelets,
granulocytes, monocytes; in addition, its determination may be
technically difficult (Vermeulen et al, 2002). Therefore, we decided
not to include the studies relating circulating VEGF to survival in
our meta-analysis (MA).
Many observational retrospective studies have concluded that
MVD is inversely related to survival in CRC, but other studies did
not reach this conclusion (Poon et al, 2003). To determine whether
angiogenesis, assessed by its surrogate end point MVD, and by the
expression of the main angiogenic factor VEGF, is prognostic
factor in CRC, we undertook a systematic review of the literature
with a meta-analysis. Meta-analyses of observational studies may
provide a useful tool for understanding and quantifying sources of
variability in results across studies (Stroup et al, 2000). Received 12 January 2006; revised 20 April 2006; accepted 21 April 2006
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sThe aim of our study was to test the hypothesis that initially
assessed MVD or VEGF expression would predict overall survival
(OS colon cancer-related death) and/or relapse-free survival (RFS,
recurrence at any site) in the global population of operated colon
cancer patients. By doing so, we tried to contribute to convert
MVD and/or VEGF expression from candidate to accepted
prognostic factors in CRC. Actually, we performed four major
meta-analyses including studies dealing with either MVD or VEGF
expression for both OS and RFS. We also tried to study the
relationship between MVD or VEGF expression and survival across
various stages of CRC. Finally, we were interested to determine
which of the two markers might be considered as the best
angiogenic prognostic factor in localised or metastatic disease.
MATERIALS AND METHODS
Publication selection
We performed our meta-analysis according to a predefined written
protocol. To be eligible, studies had to deal with colon or rectum
cancer, whatever the stage at inclusion of patients in the individual
studies, and to assess the relationship between MVD or VEGF
expression on one side and RFS or OS on the other side. Studies
(full articles) were identified by an electronic search using online
PubMed, with two distinct sets of key words used simultaneously
in each set, namely ‘colorectal cancer, neovascularization, prog-
nosis’ and ‘colorectal cancer, VEGF expression, prognosis’. Last
query was updated on 7 October 2004. We did another electronic
search with the same key words using online EMBASE, which was
unable to retrieve additional pertinent references. Our initial
selection of articles relied on careful reading of their abstracts.
Abstracts were reviewed from ASCO proceedings of the annual
meetings from 1998 to 2004, but no additional data were found.
We also screened references from the relevant literature, including
all of the identified studies, but also reviews and editorials
(Papamichael, 2001; Poon et al, 2003). We wrote or e-mailed to the
authors of 20 studies (see Appendix A) for additional information
and, in 5 occasions obtained the data needed for the meta-analytic
calculations (Choi et al, 1998; Ishikawa et al, 1999; Harada et al,
2001; Khorana et al, 2003; Galizia et al, 2004). We tried carefully to
avoid duplication of data, by examining for each publication the
names of all authors and the different medical centres involved.
We excluded studies when their recruitment came from two
distinct retrospective cohorts with different survivals (Banner et al,
1998; Nanashima et al, 1998; Barozzi et al, 2002; Saad et al, 2004),
because we deemed their results could be biased.
Methodological assessment
Information was carefully extracted from all full publications in
duplicate by the two readers (Gae ¨tan Des Guetz and Bernard
Uzzan), using a standardised data collection form, including the
following items: complete reference of the publication, original
publication or update of a former publication, mode of making up
of the series of cases, median duration of follow-up, number of
patients included in the study, mean or median age, sex, anticancer
treatment(s) during follow-up, histological type (adenocarcinoma
or mucinous), tumour size, stage of disease, grade (good, moderate
or poor differentiation), nodal status, optical reading of the slides
with or without Chalkley count or image analysis system, number
of readers of the slides, blinded reading (reader of the slides
unaware of clinical information), type(s) of immunohistochemical
staining, number of hot spots examined, magnification used, area
of the field read, cutoff value for MVD (median MVD, unless
otherwise stated, for example optimal cu-off (Takebayashi et al,
1996; Galindo Gallego et al, 2000), semiquantitative intensity of the
VEGF expression (0, þ, þþ or þþþ), number of events in
each category of MVD or VEGF, RFS or OS or both, and results of
uni- and multivariate analyses. Chalkley count was used in two
studies (White et al, 2002; Li et al, 2003). Disagreements were
resolved by consensus between the two readers. In case of
persistent disagreement, the final decision was made by our
experts (Ge ´rard Perret for clinical evaluation, and Michel Cucherat
for methodological and statistical assessment of data). We did not
set a predefined minimal number of patients for a study to be
included in our meta-analysis, nor a minimal duration of median
follow-up. We did not weigh each study by a quality score, because
no such score has received general agreement for use in a meta-
analysis, especially of observational studies, making more difficult
the evaluation of its usefulness (Altman, 2001). Studies were not
blinded to our readers, but exclusions were always decided without
knowledge of the global result of each study. When duplicate
studies were retrieved, we included in our systematic review, the
study involving the highest number of patients from which data
could be extracted (usually the latest). This was done to avoid
overlapping between cohorts. Studies were usually retrospective,
but sometimes consisted in a cohort of consecutive patients.
Although their methodological quality and the reliability of their
conclusions were variable, their design was almost similar, a
favourable condition for our meta-analysis.
Statistical methods
In each study, the relationship between MVD or VEGF expression
and survival was considered significant when the P-value for the
statistical test comparing survival distributions between the groups
with high and low MVD (usually with median MVD as cutoff) was
inferior to 0.05 in univariate analysis (two-tailed test). A study was
termed ‘positive’ or conclusive when a high MVD predicted poorer
survival and ‘negative’ or inconclusive when a high MVD did not
predict a poor survival. In a few studies, a high MVD even
predicted better survival (Lindmark et al, 1996; Abdalla et al, 1999;
Prall et al, 2003). Whenever possible, the parameter MVD was
considered as a binary outcome and dichotomised by using its
observed median. For the quantitative aggregation of survival
results, we measured the impact of MVD on survival by estimating
the risk ratio (RR) between the high or low MVD groups. For each
trial, this RR was estimated by a method depending on the data
provided in the publication. The simplest method consisted in the
direct collection of RR, hazard ratio, or odds ratio, and their 95%
confidence interval (CI) from the original article (Amaya et al,
1997; Tanigawa et al, 1997; Ishigami et al, 1998; Vermeulen et al,
1999; Maeda et al, 2000; White et al, 2002; Kaio et al, 2003b; Zheng
et al, 2003; Galizia et al, 2004; Liang et al, 2004; Tamura et al,
2004). If not available, we looked at the total numbers of events
and the numbers of patients at risk in each group to determine the
RR estimate. When data were only available as graphical survival
plots, the calculations were carried out only if the number of steps
on the curves equalled the number of events given in the
publication, assuming that the rate of censored patients was
constant during the study follow-up (Parmar et al, 1998). In two
studies, MVD was expressed as a continuous variable with no
possibility to convert the corresponding HRs to their dichotomous
counterparts so that they could not be incorporated into our meta-
analytic calculations (Takebayashi et al, 1996; Lackner et al, 2004).
The heterogeneity between studies being difficult to investigate
reliably, we chose to incorporate the assumption that the effect on
survival between studies was not identical but followed some
unknown distribution. Thus, we calculated a pooled random RR
estimate and its 95% CI by using a random-effect model (Der
Simonian and Laird’s method). This method is more conservative
because the CI around the random RR pooled estimate is wider
than the CI around the fixed RR pooled estimate. By convention,
an observed RR 41 implied a worse prognosis in the high MVD or
VEGF expression group. The detrimental impact of angiogenesis
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son survival was deemed statistically significant whenever the lower
of the 95% CI of the overall RR was 41. Comparisons of
proportions of studies with or without various characteristics were
made by w
2 tests. The statistical calculations for our meta-analyses
were performed with EasyMA.net, Internet distributed application
(Department of Clinical Pharmacology, Cardiology Hospital,
Lyons, France) (Cucherat et al, 1997).
RESULTS
Our electronic data search using online PubMed and EMBASE
retrieved a total of 153 references (107 dealing with MVD and 46
dealing with VEGF expression; full list available on request)
including duplicate references since some publications studied
both markers. After exclusion of the references which were out of
the scope of our meta-analysis, there remained 45 studies dealing
with MVD (see Appendix B) and 27 dealing with VEGF expression
(see Appendix C), representing a total of 56 independent studies.
Some of these articles did not fulfil our inclusion criteria (mainly
because they did not mention survival data), six for MVD
(Vermeulen et al, 1995; Banner et al, 1998; Nanashima et al,
1998; Kondo et al, 2000; Barozzi et al, 2002; Saad et al, 2004) and
five for VEGF (Nanashima et al, 1998; Kondo et al, 2000; Seto et al,
2000; Barozzi et al, 2002; Saad et al, 2004). One study was written
in Chinese language, with an English abstract and did not seem to
mention survival data (Liu et al, 1999). Some publications
corresponded to duplicate studies of the same marker, six for
MVD (Amaya et al, 1997; Abdalla et al, 1999; Galindo-Gallego et al,
2000; Furudoi et al, 2002; Kaio et al, 2003b; Onogawa et al, 2004)
and four for VEGF expression (Amaya et al, 1997; Furudoi et al,
2002; Kaio et al, 2003b; Onogawa et al, 2004) (Figure 1).
Almost all studies (n¼40) used Dukes staging or derived
classification (Astler-Coller). Two studies used only TNM staging
(Tanigawa et al, 1997; Fox et al, 1998). Several studies used both
classifications (see Appendix D). To better describe the patients
included in our meta-analysis, we used Dukes staging whenever
possible. For one study (Ishikawa et al, 1999), in the absence of
lymph node involvement or metastasis, we could convert stage
T1–3N0M0 into stage A or B.
The main features of the eligible studies for MVD are
summarized in Table 1. Thirty-two independent studies represent-
ing 3496 patients with mean age of 64.7 years (1740 male patients,
1400 female patients) included 1449 colon and 673 rectum cancers.
These studies included 286 stage A, 1315 stage B, 1085 stage C and
388 stage D. There were only eight series of consecutive patients
(Lindmark et al, 1996; Ishikawa et al, 1999; Vermeulen et al, 1999;
Pietra et al, 2000; Prall et al, 2003; Shan et al, 2003; Galizia et al,
2004; Liang et al, 2004) and one prospective study (Nanni et al,
2002), compared to 23 retrospective studies.
Finally, statistical calculations could be performed in 22 studies
for MVD including nine studies (n¼957) for RFS (Engel et al,
1996; Takahashi et al, 1997; Choi et al, 1998; Ishikawa et al, 1999;
Galindo Gallego et al, 2000; Nanni et al, 2002; Shan et al, 2003;
Galizia et al, 2004; Liang et al, 2004) and 18 for OS (n¼2383) (see
Appendix E). High MVD significantly predicted poor RFS
(RR¼2.32; 95% CI: 1.39–3.90; Po0.001) and poor OS
(RR¼1.44; 95% CI: 1.08–1.92; P¼0.01).
Meta-analysis was also performed to relate VEGF expression and
survival across all exploitable studies. The main features of eligible
studies for VEGF are summarized in Table 2. Eighteen indepen-
dent studies with 2050 patients with mean age 63.3 years (1041
male patients, 750 female patients) included 1104 colon cancers
and 202 rectum cancers. These studies included 130 stage A, 472
stage B, 626 stage C and 149 stage D. Statistical calculations were
performed for VEGF in 17 studies, including nine studies
(n¼1064) (Amaya et al, 1997; Takahashi et al, 1997; Cascinu
et al, 2000; Maeda et al, 2000; Cascinu et al, 2001; Cascinu et al,
2002; Nanni et al, 2002; White et al, 2002; Galizia et al, 2004) for
RFS and 10 for OS (n¼1301) (Ishigami et al, 1998; Tokunaga et al,
1998; Lee et al, 2000; Harada et al, 2001; Nanni et al, 2002; White
et al, 2002; Kaio et al, 2003b; Khorana et al, 2003; Zheng et al, 2003;
Tamura et al, 2004). High VEGF significantly predicted poor RFS
(RR¼2.84; 95% CI: 1.95–4.16; Po0.001) and poor OS (RR¼1.65;
95% CI: 1.27–2.14; Po0.001). All four major meta-analyses gave
statistically significant results, favouring a link between high MVD
and VEGF expression and poor survival (see Figure 2).
We have shown previously in our meta-analysis relating MVD to
survival in breast cancer that CD 31 and CD 34 were the best
markers to predict survival compared with factor VIII (Uzzan
et al, 2004). Our present work confirms these findings for CRC.
Actually a specific meta-analysis performed by using CD 31/CD34
in CRC gave higher RRs than the global meta-analysis (data not
shown).
To determine whether MVD and/or VEGF expression are
prognostic factors more suited to limited (stage A/B) or advanced
disease (stage C/D), we divided the studies into those including a
majority of limited forms, those including a majority of advanced
forms and those where limited and advanced forms were balanced
(mixed studies) which we omitted for being too few and ill-defined.
For RFS and MVD, the RR for the studies with advanced forms
(n¼3) was higher than the RR for the studies with limited forms
(n¼7) (3.23 vs 2.49, these two** RRs being significantly different
from 1 but not different from each other). These results are in
favour of a prognostic role of MVD either in local or in advanced
disease. For VEGF and RFS studies with localised disease (n¼4),
we found a RR of 4.05 (Po0.001) compared with a RR of 3.41
(Po0.001) for the studies with advanced disease (n¼2). For MVD
and VEGF expression and for OS, the RRs of the studies with
limited and advanced disease were also significantly 41, but less
significant than for RFS.
Finally, we compared the ability of both angiogenic markers to
predict survival by calculating the ratio of their RRs; for RFS, this
ratio RR VEGF/RR MVD was found to be 1.22 (95% CI: 0.50–2.98),
not significantly different from 1. However, the 95% CI width was
smaller for VEGF than for MVD. The results were similar for OS.
DISCUSSION
Our overview and meta-analysis of all published studies from
which statistical data could be obtained or calculated showed that
high MVD and VEGF expression, markers of angiogenesis, did
indeed predict poor survival in patients with CRC.
However, our conclusions should be tempered for several
reasons. First, the overall link we elicited between MVD and
153 Studies from Pub Med
108 Out of the scope
6 Duplicates studies 
11 No inclusion criteria
1 Article in Chineese
32 Studies MVD
10 Without exploitable survival statistics 1 Without exploitable survival statistics
18 Studies VEGF
22 Studies analysed 17 Studies analysed
Figure 1 Flow chart of the meta-analysis.
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sTable 1 Main characteristics of the studies relating microvessel density to MVD survival
First author
Year of issue (reference)
Study
from
PubMed
Study
design N (M/F) Colon (n)
Rectum
(n)
Blinded
reading Reader(s) (n)
Mode of
reading Antibody Extension RR estimate Survival analysis Results
Galizia et al (2004) Yes C 104 (73/31) 104 0 Yes 2 Optical CD34 Limited Given by authors OS, RFS Negative
Lackner et al (2004) Yes R 70 (39/31) 49 21 ? ? Optical FVIII
CD34
Mixed Missing ? Positive
Liang et al (2004) No C 114 (60/54) 77 37 Yes 1 Optical CD34 Advanced Reported in text RFS Positive
Kaio et al (2003a,b) Yes R 152 (94/58) ? ? ? ? Optical CD34 Mixed Survival curves OS Negative
Prall et al (2003) Yes C 173 (87/86) ? ? ? 1 Optical FVIII Mixed Survival curves OS Inverse
Li et al (2003) Yes R 111 (65/46) 83 28 ? ? Chalkley CD105
CD34
Mixed Survival curves OS Positive
Shan et al (2003) Yes C 104 (55/49) 72 32 Yes 2 Optical FVIII Limited Data extrapolated OS, RFS Negative
Zheng et al (2003) Yes R 97 (58/39) ? ? ? ? Optical CD34 Mixed Reported in text OS Positive
Cianchi et al (2002) Yes R 84 (60/24) 0 84 Yes 2 Optical CD31 Limited Data extrapolated OS Negative
Nanni et al (2002) No P 263 (137/126) 263 0 Yes 2 Optical FVIII Mixed Data extrapolated OS, RFS Negative
White et al (2002) Yes R 84 (42/42) 62 22 Yes 2 Chalkley CD31
FVIII
Limited Missing OS, RFS Inverse
Sokmen et al (2001) Yes R 29 (18/11) 0 29 Yes 2 Automated FVIII Mixed Survival curves OS Positive
Galindo-Gallego et al (2000) Yes R 126 (70/56) 87 39 ? ? Optical CD34 Limited Survival curves OS, RFS Negative
Pietra et al (2000) Yes C 119 (62/57) 78 41 Yes 2 Optical CD31 Mixed Missing OS, RFS Negative
Van Triest et al (2000) Yes R 32 (13/19) 26 6 Yes 2 Optical CD31 Mixed Missing Missing ND
Giatromanolaki et al (2002) No R 106 (65/41) 77 29 ? ? Optical CD31 Mixed Missing OS Positive
Ishikawa et al (1999) Yes C 57 (34/23) 0 57 Yes 2 Optical CD31 Limited Survival curves RFS Positive
Sternfeld et al (1999) Yes R 146 (?) 70 76 ? 1 Optical CD31 Limited Survival curves OS Positive
Vermeulen et al (1999) No C 145 (75/70) 109 36 ? ? Optical CD31 Advanced Reported in text RFS Positive
Choi et al (1998) Yes R 127 (72/55) ? ? Yes 2 Optical FVIII Advanced Survival curves OS, RFS Positive
Fox et al (1998) Yes R 36 (14/22) 36 0 ? ? Optical FVIII ND Survival curves OS Negative
Pavlopoulos et al (1998) Yes R 106 (56/50) ? ? Yes ? Automated FVIII Limited Missing Missing Negative
Tanigawa et al (1997) Yes R 133 (76/57) ? ? Yes 2 Optical CD34 Advanced Reported in text OS Positive
Takahashi et al (1997) No R 27 (12/15) 27 0 Yes 1 Optical FVIII Limited Survival curves RFS Positive
Engel et al (1996) No R 35 (21/14) ? ? Yes 2 Optical CD31 Limited Data extrapolated RFS Positive
Lindmark et al (1996) No C 212 (90/122) 124 88 Yes 1 Optical FVIII Limited Data extrapolated OS Inverse
Mooteri et al (1996) Yes R 32 (?) ? ? Yes ? Optical FVIII Advanced Missing Missing Negative
Takebayashi et al (1996) Yes R 166 (108/58) ? ? Yes 2 Optical FVIII Limited Survival curves OS Positive
Tomisaki et al (1996) No R 175 (98/77) ? ? ? 1 Optical FVIII Advanced Data extrapolated OS Negative
Frank et al (1995) Yes R 105 (53/52) 105 0 Yes ? Optical FVIII Limited Missing Missing Positive
Bossi et al (1995) Yes R 178 (?) ? ? ? 1 Optical CD31 Mixed Missing Missing Negative
Saclarides et al (1994) Yes R 48 (33/15) 0 48 Yes 1 Optical FVIII Mixed Missing Missing ND
C corresponds to studies including consecutive patients, R to retrospective studies without inclusion of consecutive patients. Extension means a predominance of limited forms (A/B), of advanced forms (C/D) or a balance between
limited and advanced forms among the same study (mixed). RR estimate was either reported in text, or provided by mail by authors, or extrapolated from the data provided by authors in text, or estimated from the survival curves. A
positive result means that there was an inverse relationship between MVD and survival, an inverse result means that there was a direct relationship between MVD and survival, and a negative result that there is no relationship.
‘Readers’ are readers of the histologic slides, ‘blinded reading’ means that readers of the slides were unaware of the clinical outcome of patients, and ‘?’ corresponds to missing data.
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sTable 2 Main characteristics of the studies relating VEGF expression to survival
First author
Year of issue
(reference)
Study
from
PubMed
Study
design N (M/F) Colon (n)
Rectum
(n)
Blinded
reading
Reader(s)
(n) VEGF assessment Extension RR Estimate Survival analysis Results
Galizia et al (2004) Yes C 104 (73/31) 104 0 Yes 2 VEGF Limited Reported in text OS, RFS Positive
Tamura et al (2004) Yes R 49 (35/14) 26 23 Yes 2 VEGF Advanced Reported in text OS Negative
Kaio et al (2003a,b) Yes R 152 (94/58) ? ? ? ? VEGF-C Mixed Reported in text OS Positive
Khorana et al (2003) Yes C 131 (69/62) 131 0 Yes 1 VEGF Advanced Given by authors OS Negative
Zheng et al (2003) Yes R 97 (58/39) ? ? ? ? VEGF Mixed Reported in text OS Negative
Cascinu et al (2002) Yes C 79 (44/35) 0 79 Yes 2 VEGF Advanced Reported in text RFS Positive
Nanni et al (2002) Yes P 263 (137/126) 263 0 ? 2 VEGF Mixed Data extrapolated OS, RFS Negative
White et al (2002) Yes R 84 (42/42) 62 22 Yes 2 VEGF-D
VEGFR-3
Limited Reported in text OS, RFS Positive
Cascinu et al (2001) Yes C 150 (90/60) 150 0 Yes 2 VEGF Advanced Data extrapolated RFS Positive
Harada et al (2001) Yes C 259 (?) ? ? Yes 2 VEGF Mixed Survival curves OS Positive
Cascinu et al (2000) Yes C 121 (71/50) 121 0 Yes 2 VEGF Limited Data extrapolated RFS Positive
Lee et al (2000) Yes C 145 (80/65) 102 43 Yes 2 VEGF Limited Survival curves OS Negative
Maeda et al (2000) Yes R 100 (70/30) ? ? Yes 2 VEGF Mixed Reported in text RFS Positive
Van Triest et al (2000) Yes R 32 (13/19) 26 6 Yes 2 VEGF Mixed Missing Missing ND
Ishigami et al (1998) Yes R 60 (40/20) 31 29 ? ? VEGF (Northern blot) Advanced Reported in text OS Positive
Tokunaga et al (1998) Yes R 61 (34/27) 61 0 ? 2 VEGF isoform pattern ? Survival curves OS Positive
Takahashi et al (1997) Yes R 27 (12/15) 27 0 Yes Image analyzer VEGF Limited Data extrapolated RFS Positive
Amaya et al (1997) No R 136 (79/57) ? ? Yes 2 VEGF Advanced Reported in text RFS Positive
C represents studies including consecutive patients, R retrospective studies including non consecutive patients, and P prospective studies. Extension means a predominance of limited forms (A, B), of advanced forms (C, D) or a balance
between the 2 forms (mixed). RR estimate was either reported in text, or provided by mail by authors, or extrapolated from the data provided by authors in text, or estimated from the survival curves. A positive result means an
inverse relationship between VEGF expression and survival and a negative result means no relationship. ‘Readers’ are readers of the histologic slides, ‘blinded reading’ means that readers of the slides were unaware of the clinical
outcome of patients, and ‘?’ corresponds to missing data.
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Clinical Studiessurvival, although statistically significant, was rather weak, with a
global RR of 1.44 for OS and 2.32 for RFS. However, for VEGF
expression, these links were stronger (1.65 for OS; 2.84 for RFS).
Empirically, RRs 42 are considered strongly predictive (Hayes
et al, 2001). Both markers appeared more predictive for RFS than
for OS, not surprisingly since OS is a more stringent parameter
than RFS, harder to be influenced by treatments. We performed
the meta-analyses including selectively the studies involving
consecutive patients, supposed to be of better methodological
quality, and found, rather unexpectedly, that the relation between
survival and markers of angiogenesis was not improved for RFS,
and even deteriorated for OS.
Our meta-analysis has several limitations. First, the level of
evidence provided by MA of retrospective observational studies is
lower than that of randomised controlled trials. Also, it relied on
publications and not on individual data. But a meta-analysis on
individual data would require the implication of many pathologists
and a time-consuming processing of materials because of the large
number of patients included in the studies and especially of their
rather poor quality. There were several potential sources of
heterogeneity between studies, but the Der Simonian and Laird
method we used (random effect model) took them into account.
Studies may have differed in the baseline characteristics of
patients included (age, tumour size, and stage), the adjuvant
treatment they might have received for their cancer, the number of
patients, the duration of follow-up. We attempted to minimise
publication bias by making our literature search as complete as
possible, using two databases (PubMed and EMBASE), reviewing
ASCO meetings proceedings from 1998 to 2004 and crosschecking
references. The discrepancies in the conclusions of various
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spublished studies could have encouraged researchers to publish
their data whatever their results, thus limiting such publication
bias. All publications but one (Liu et al, 1999) were written in
English language. The immunohistochemical marker used to
assess MVD, or the method of microvessel count itself were
sources of variability and represented potential selection biases.
Weidner et al (1991) used an antibody against factor VIII-related
antigen, staining mainly mature vessels and cross-reacting
with lymphatic endothelium. This marker remained the most
used in the studies we reviewed. Several recent studies used
antibodies directed against CD31 or CD34, best prognostic
markers in CRC.
Many variations to the method of MVD assessment exist,
although most studies used a technique similar to that of Weidner
et al (1991). The size of the area examined varied between studies.
Some authors considered the mean or the highest value among
three or more determinations of MVD at different fields of the
same hot spot (Saclarides et al, 1994; Lindmark et al, 1996;
Tanigawa et al, 1997; van Triest et al, 2000). Some measured MVD
as the mean or highest value at several hot spots (Sokmen et al,
2001; Shan et al, 2003; Galizia et al, 2004; Lackner et al, 2004). The
choice of the cutoff value for MVD varied among studies, many
used median MVD. In future studies, the assessment of these
angiogenic prognostic factors should be better standardised,
especially for patients for whom adjuvant therapy is recommended
(Vermeulen et al, 2002).
Prognostic biomarkers may be useful for identifying high-risk
patients, leading to an improvement in their clinical or therapeutic
management (Weitz et al, 2005). Whereas in stage III CRC
patients, adjuvant chemotherapy has been consistently shown to
increase OS, in stage II it provides a small benefit, still uncertain.
Meta-analyses gave conflicting results, one concluding to a small
beneficial effect of chemotherapy (Mamounas et al, 1999) and the
other to the absence of benefit (Gill et al, 2004). No study analysed
separately the prognostic role of angiogenic markers among colon
or rectum cancers. Microvessel density or VEGF expression might
be predictive factors of the response to anti-angiogenic drugs
(bevacizumab), now in phase III or IV trials (Hurwitz et al, 2004).
In metastatic CRC, MVD and VEGF expression did not predict the
favourable response to bevacizumab in one retrospective study
derived from the pivotal efficacy trial (Jubb et al, 2006).
Conversely, VEGF predicted rectal tumour response to preopera-
tive radiotherapy (Zlobec et al, 2005). Therefore, pathological
markers such as MVD or VEGF expression would be helpful for
individualisation of patients who would benefit from anti-
angiogenic therapy.
We found a trend to a relationship between tumour stage
(limited, advanced) and the capacity of angiogenesis markers to
predict survival. There are pathophysiological grounds for such a
relationship, since angiogenesis is a very early phenomenon in
colon carcinogenesis and it is also essential to metastasis (Garcea
et al, 2004; Wali et al, 2005). However, our findings might also be
artefactual, since the definition of the three categories of studies
was imprecise and there were few studies. According to our results,
VEGF seemed to be a rather better angiogenic predictor of survival
than MVD, due to a narrower 95% CI although the ratio of their
RRs was not significantly different from 1. These last results should
be interpreted cautiously, since this double factor analysis would
ideally be performed on individual patients data.
The following recommendations should be made to future
authors: include a large series of consecutive patients from a single
cohort, stratify by tumour stage, fully describe the clinical
characteristics of the study population, use antibodies directed
against either CD31 or CD34 for immunostaining, present the
results both as comparison of survival curves and as multivariate
regression analysis and provide a full description of survival events
to allow calculations. Future studies should include more
homogeneous populations and should be prospective.
To conclude, our meta-analysis, representing a quantified
synthesis of all published studies, found a statistically significant
inverse relationship between angiogenesis, assessed by MVD or
VEGF expression, and survival, confirming that, like breast cancer,
human invasive colorectal cancer is an angiogenesis-dependent
malignancy.
Addendum
Our PubMed query was ultimately updated to 14 February 142006.
The relation between survival and MVD was assessed in only two
additional articles, a positive study including 60 patients for RFS
(Acikalin et al (2005) Tumour angiogenesis and mast cell density
in the prognostic assessment of colorectal carcinomas. Dig Liver
Dis 37: 162–169) and a study of borderline significance including
92 patients for OS (Yonenaga et al (2005) Absence of smooth
muscle actin-positive pericyte coverage of tumor vessels correlates
with hematogenous metastasis and prognosis of colorectal cancer
patients. Oncology 69: 159–166). The relation between survival and
VEGF expression was assessed in two other articles, one negative
study including 109 stage II colon cancers assessed for OS (Ochs
et al (2004) Expression of vascular endothelial growth factor and
HER2/neu in stage II colon cancer and correlation with survival.
Clin Colorectal Cancer 4: 262–267) and one positive study
including 69 patients assessed for RFS and OS (Ferroni et al
(2005) Prognostic value of vascular endothelial growth factor
tumor tissue content of colorectal cancer. Oncology 69: 145–153).
After incorporation into our meta-analysis of these four additional
studies, the global RRs were very similar to the old ones, which
could be expected from the small numbers of patients added and
consequently the large CIs surrounding the RRs of these new
studies. For MVD, the new RRs were 2.43 (95% CI: 1.49–3.96) for
RFS and 1.46 (95% CI: 1.10–1.92) for OS. For VEGF, the new RR
was 2.92 (95% CI: 2.04–4.17) for RFS (the RR for OS did not
change. Thus, the conclusions of our four meta-analyses are
identical before and after incorporation of these four new studies.
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Tokunaga et al, 1998; Ishikawa et al, 1999; Sternfeld et al, 1999; Lee
et al, 2000; Pietra et al, 2000; van Triest et al, 2000; Harada et al,
2001; Giatromanolaki et al, 2002; White et al, 2002; Khorana et al,
2003; Galizia et al, 2004; Lackner et al, 2004).
Appendix B
List of the 45 references dealing with microvessel density which
were within the scope of our meta-analysis (Saclarides et al, 1994;
Bossi et al, 1995; Frank et al, 1995; Vermeulen et al, 1995; Engel
et al, 1996; Lindmark et al, 1996; Mooteri et al, 1996; Takebayashi
et al, 1996; Tomisaki et al, 1996; Amaya et al, 1997; Takahashi et al,
1997; Tanigawa et al, 1997; Banner et al, 1998; Choi et al, 1998; Fox
et al, 1998; Nanashima et al, 1998; Pavlopoulos et al, 1998; Abdalla
et al, 1999; Ishikawa et al, 1999; Liu et al, 1999; Sternfeld et al,
1999; Vermeulen et al, 1999; Galindo-Gallego et al, 2000; Galindo
Gallego et al, 2000; Kondo et al, 2000; Pietra et al, 2000; van Triest
et al, 2000; Sokmen et al, 2001; Barozzi et al, 2002; Cianchi et al,
2002; Furudoi et al, 2002; Giatromanolaki et al, 2002; Nanni et al,
2002; White et al, 2002; Kaio et al, 2003a,b; Li et al, 2003; Prall
et al, 2003; Shan et al, 2003; Zheng et al, 2003; Galizia et al, 2004;
Lackner et al, 2004; Liang et al, 2004; Onogawa et al, 2004; Saad
et al, 2004).
Appendix C
List of the twenty-seven references dealing with VEGF expression
which were within the scope of our meta-analysis (Amaya et al,
1997; Takahashi et al, 1997; Ishigami et al, 1998; Nanashima et al,
1998; Tokunaga et al, 1998; Liu et al, 1999; Cascinu et al, 2000;
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sKondo et al, 2000; Lee et al, 2000; Maeda et al, 2000; Seto et al,
2000; van Triest et al, 2000; Cascinu et al, 2001; Harada et al, 2001;
Barozzi et al, 2002; Cascinu et al, 2002; Furudoi et al, 2002; Nanni
et al, 2002; White et al, 2002; Kaio et al, 2003a,b; Khorana et al,
2003; Zheng et al, 2003; Galizia et al, 2004; Onogawa et al, 2004;
Saad et al, 2004; Tamura et al, 2004).
Appendix D
List of the twelve references using Dukes and TNM classification
Takebayashi et al, 1996; Choi et al, 1998; Tokunaga et al, 1998;
Vermeulen et al, 1999; Lee et al, 2000; Maeda et al, 2000; Harada
et al, 2001; Sokmen et al, 2001; Cianchi et al, 2002; Khorana et al,
2003; Galizia et al, 2004.
Appendix E
List of the eighteen references dealing with microvessel density and
overall survival for which statistical calculation were performed
(Lindmark et al, 1996; Takebayashi et al, 1996; Tomisaki et al,
1996; Tanigawa et al, 1997; Choi et al, 1998; Fox et al, 1998;
Sternfeld et al, 1999; Vermeulen et al, 1999; Galindo Gallego et al,
2000; Sokmen et al, 2001; Cianchi et al, 2002; Nanni et al, 2002;
Kaio et al, 2003b; Li et al, 2003; Prall et al, 2003; Shan et al, 2003;
Zheng et al, 2003; Galizia et al, 2004).
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